Crispr Therapeutics

We track 2 ClinicalTrials.gov studies led by Crispr Therapeutics. The portfolio skews toward Phase 1 (1 trials).

2 clinical trials sponsored by Crispr Therapeutics.

Pipeline by Phase

PhaseTrialsDistribution
Phase 1 1
50%
Phase 2 1
50%

Trial Status Breakdown

Trials by Crispr Therapeutics

A Phase 1 Dose Evaluation Study of the Safety and Preliminary Efficacy of Anti-CD19 Allogeneic CRISPR-Cas9-Engineered T Cells (CTX112) in Adult Subjects With Refractory Autoimmune Disease

NCT06925542 · RECRUITING · Phase 1

A Phase 1/2 Dose Evaluation and Cohort Expansion Study of the Safety and Efficacy of Anti-CD70 Allogeneic CRISPR-Cas9-Engineered T Cells (CTX131) in Adult Subjects With Relapsed/Refractory Hematologic Malignancies

NCT06492304 · COMPLETED · Phase 2

Frequently Asked Questions

How many clinical trials does Crispr Therapeutics sponsor?

Crispr Therapeutics currently sponsors 2 clinical trials tracked on ReadTheTrial. These span Phase 1, Phase 2.

What conditions does Crispr Therapeutics research?

Crispr Therapeutics conducts research across multiple therapeutic areas. Browse the trial listings for details.

Is Crispr Therapeutics recruiting for clinical trials?

Yes, Crispr Therapeutics currently has 1 trial that are actively recruiting participants. Check individual trial pages for eligibility criteria and locations.

Explore More